Back to the main directory
EarningsReview / Equity
- Racing Force SpA - Pas de faux départ by MidCap Partners
- An introduction to Rentokil by BNP Paribas Exane
- What to expect from AI, generative AI and ChatGPT from an ESG perspective? by Oddo BHF
- Racing Force SpA - No False Starts by MidCap Partners
- Interparfums - Once Again, a Remarkable Performance by MidCap Partners
- NOKIA: RDOS. 1T’23 (ANÁLISIS BANCO SABADELL) by Sabadell
- Mendus - Momentum gathering across the pipeline by Edison Investment Research
- Respiri - Wheezo commercialization picking up pace by Edison Investment Research
- Singapore Gaming by HSBC
- Solid quarter, FY23 NII guidance looks conservative by BNP Paribas Exane
- China Technology by HSBC
- OpGen - Fisher deal broadens US commercialization opportunity by Edison Investment Research
- Strong Q1 23 trading update by BNP Paribas Exane
- Itaú BBA Credit Research on Usiminas: Quick Take on 1Q23 Results by Itau
- BANKINTER: RDOS. 1T’23 (ANÁLISIS BANCO SABADELL) by Sabadell
- And the winner is? by BNP Paribas Exane
- Active in a challenging market by BNP Paribas Exane
- (Lots) Sweet about me by BNP Paribas Exane
- Ericsson (Buy, TP: SEK76.00) - Inventory-driven trough in Q2e by DnB Markets
- GN Group (Buy, TP: DKK250.00) - Set to narrow Hearing guidance by DnB Markets
- Surgical Science (Buy, TP: SEK211.00) - Stable quarter ahead by DnB Markets
- Aker Biomarine (Hold, TP: NOK38.00) - Lukewarm Q1e by DnB Markets
- Telia Company (Buy, TP: SEK34.00) - Focus on structural part of Op.FCF by DnB Markets
- Equinor (Buy, TP: NOK370.00) - Q1e another ‘net cash build’ quarter by DnB Markets
- Coloplast (Hold, TP: DKK960.00) - Guidance raise unlikely in Q2 by DnB Markets
- Que penser de l’IA, l’IA générative et ChatGPT d’un point de vue ESG ? by Oddo BHF
- BANKINTER: 1Q’23 RESULTS (ANÁLISIS BANCO SABADELL) by Sabadell
- Que penser de l’IA, l’IA générative et ChatGPT d’un point de vue ESG ? by Oddo BHF
- Kerlink - A New Beginning! by MidCap Partners
- Vetoquinol - Q1 Stable Excluding Overstocking Effect by MidCap Partners
- Flawed and Unreined by BNP Paribas Exane
- discoverIE Group - Upgrading on strong close to FY23 by Edison Investment Research
- Bankinter - Better guidance lifts TP by 2%; reiterating Buy for top pick by JB Capital Markets
- We see large EPS upgrades ahead by BNP Paribas Exane
- 中国科技行业 by HSBC
- On the road with JCDecaux by BNP Paribas Exane
- Is there really cause for concern? by BNP Paribas Exane
- Support from structural savings by BNP Paribas Exane
- All cheap, but not all cheerful by BNP Paribas Exane
- Zealand Pharma - In a sweet spot by Danske Bank Equity Research
- Volvo - Solid order intake is yet another positive surprise by Danske Bank Equity Research
- Cloud Giveth, And Cloud Taketh Away by BNP Paribas Exane
- Solid Q1 with high visibility of growth ahead by BNP Paribas Exane
- Enea (Hold, TP: SEK95.00) - Underlying business still shrinking by DnB Markets
- Surgical Science (Buy, TP: SEK211.00) - Stable quarter ahead by DnB Markets
- Grieg Seafood (Buy, TP: NOK90.00) - Mixed performance in Q1e by DnB Markets
- Aker BP (Buy, TP: NOK370.00) - On track for guidance beat by DnB Markets
- SCA (Buy, TP: SEK190.00) - Buying opportunity in quality by DnB Markets
- Husqvarna (Sell, TP: SEK85.00) - Time for the real test now by DnB Markets
- Coloplast (Hold, TP: DKK960.00) - Guidance raise unlikely in Q2 by DnB Markets